Medicenna Therapeutics Corp (MDNA) NPV

Sell:0.95 CADBuy:1.00 CAD0.03 CAD (3.06%)

Prices delayed by at least 15 minutes
Sell:0.95 CAD
Buy:1.00 CAD
Change:0.03 CAD (3.06%)
Prices delayed by at least 15 minutes
Sell:0.95 CAD
Buy:1.00 CAD
Change:0.03 CAD (3.06%)
Prices delayed by at least 15 minutes

Company Information

About this company

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Key people

Fahar Merchant
Chairman of the Board, President, Chief Executive Officer
David Hyman
Chief Financial Officer, Corporate Secretary
Rosemina Merchant
Chief Development Officer
Albert G. Beraldo
Lead Independent Director
Karen A. Dawes
Independent Director
John Geltosky
Independent Director
Karim Lalji
Independent Director
John H. Sampson
Independent Director
Click to see more

Key facts

  • EPIC
    MDNA
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA58490H1073
  • Market cap
    CA$77.03m
  • Employees
    16
  • Shares in issue
    78.22m
  • Exchange
    Toronto Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.